Effects of the sibutramine therapy on pulmonary artery pressure in obese patients

Diabetes, Obesity and Metabolism

Volumn 6, Issue 1, 2004, Pages 50-55

  Guven, Aytekin ^a   Koksal, N ^a   Cetinkaya, A ^a   Sokmen, G ^a   Ozdemir, R ^b  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

Author keywords

Echocardiography; Heart valves; Pulmonary artery pressure; Sibutamine

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; LIPID; MAZINDOL; SIBUTRAMINE;

ADULT; AORTA VALVE DISEASE; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE MEASUREMENT; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DISEASE; HEART RATE; HUMAN; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE DISEASE; OBESITY; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION; WEIGHT REDUCTION;

EID: 0742306737     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00314.x     Document Type: Article

References (27)

1. Van Itallie TB. Worldwide epidemiology of obesity. Pharmaco Economics 1994; 5 (Suppl. 1): 1-7.
2. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2207-2212.
3. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119: 655-660.
4. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf 1999; 20: 119-131.
5. Wilson CA, Stock MJ. Drugs for the treatment of obesity. Report on the Society for Drug Research Symposium held at the School of Pharmacy, University of London on 6 July 1989. Pharm Med 1990; 4: 249-259.
6. Silverstone T. Appetite suppressants: a review. Drugs 1992; 43: 820-836.
7. Arch JRS, Kaumann AJ. β3 and atypical β-adrenoreceptors. Med Res Rev 1993; 13: 663-729.
8. Yamamato K, Masuyama T, Tanouchi J et al. Peak early diastolic filling velocity may decrease with preload augmentation: effect of concomitant increase in a rate of left atrial pressure drop in early diastole. J Am Soc Echocardiogr 1993; 6: 245-254.
9. Currie PJ, Seward JB, Chan K-L et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985; 6: 750-756.
10. Langleben D. Relearning the lessons of history: anorexigens and pulmonary hypertension. Chest 1998; 5 (Suppl. 1): 34-37.
11. Douglas JG, Munro JF, Kitchin AH et al. Pulmonary hypertension and fenfluramine. Br Med J 1981; 283: 881-883.
12. Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of pulmonary hypertension. Int Primary Pulmonary Hypertension Study Group N Engl J Med 1996; 335: 609-616.
13. Bowen R, Glicklich A, Khan M et al. Cardiac valvulopathy associated with exposure to fenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997, MMWR Morb Mortal Wkly Rep 1997; 46: 1061-1066.
14. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997; 21 (Suppl. 1): 25-29.
15. Zannad F, Gille B, Grentzinger A et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144: 508-515.
16. Bach DS, Rissanen AM, Mendel CM et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363-369.
17. 2+) in pulmonary arterial myocytes. Circ Res 1995; 77: 370-378.
18. NacCulloch KM, Osipenko ON, Gurney AM. Oxygen-sensing potassium currents in pulmonary artery. Gen Pharmacol 1999; 32: 403-411.
19. Weir EK, Reeve HL, Huang JMC et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94: 2216-2220.
20. 2+, independent of membrane potential. Am J Physiol 1999; 277: L662-L666.
21. Reeve HL, Nelson DP, Archer SL, Soper M, Weir EK. Effect of fluoxetine, phentramine, and venlafaxine on pulmonary arterial pressure and electrophysiology. Am J Physiol 1999; 276: L213-L219.
22. Perchenet L, Hilfiger L, Mizrahi J, Clement-Chomienne O. Effects of anorexinogen agents on cloned voltage-gated K+ channel hKv1.5. J Pharmacol Exp Ther 2001; 298: 1108-1119.
23. Schrefer J.ed. Mosby GenRx: a comprehensive reference for generic and brand prescription drugs. 11th edn. St. Louis: Mosby, 2001.
24. Campbell ML, Mathys ML. Pharmacologic options for the treatment of obesity. Am J Health Syst Pharm 2001; 58 (14): 1301-1308.
25. Wadden TA, Berkowitz RI, Sarwer DB et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001; 161: 218-227.
26. McMahon FG, Fujioka K, Shingh BN et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-2191.
27. Apfelbaum M, Vague P, Ziegler O et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-184.